Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis

Douglas Kazutoshi Sato, Ichiro Nakashima, Amit Bar-Or, Tatsuro Misu, Chihiro Suzuki, Shuhei Nishiyama, Hiroshi Kuroda, Kazuo Fujihara, Masashi Aoki

Research output: Contribution to journalArticlepeer-review

50 Citations (Scopus)


Fingolimod has demonstrated efficacy in patients with multiple sclerosis (MS), and patients become gradually lymphopenic after a few days of treatment, with selective reductions in CD4. + subsets. We observed an increase in the frequencies of circulating regulatory T cells after fingolimod administration. However, we also found that half of patients had increased proportion of circulating Th17 cells in CD4. + T cells after treatment (including a patient with MS relapses), whereas the others showed lower frequencies of Th17 cells, indicating some variability among patients. Further studies may confirm if slower reduction of circulating Th17 cells following fingolimod initiation predisposes to relapses.

Original languageEnglish
Pages (from-to)95-98
Number of pages4
JournalJournal of Neuroimmunology
Issue number1-2
Publication statusPublished - 2014


  • Fingolimod
  • Interleukin-17
  • Multiple sclerosis
  • Regulatory T cells
  • Th17
  • Treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis'. Together they form a unique fingerprint.

Cite this